4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.46 +1.70%

+$0.16 today

Market cap
$577.85M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.68M

Average 0.77M

FDMT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 32.6%

Gross margin was 32.6% in Q1 FY2026, up 290639.7 pp from a year earlier. On a trailing-twelve-month basis it was -12.4%, up 490439.7 pp year over year. Over 3 fiscal years it widened by 2555.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
32.6%-65.1 pp QoQ
Last fiscal yearDec 2025
91.1%+381880.2 pp YoY
LTMMar 2026
-12.4%+490439.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+290639.7 pp——
1 year+381880.2 pp——
3 years+2555.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
91.1%
Year-over-year change
+381880.2pp

Gross Margin vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's LTM Mar 2026 gross margin of -12.4% is the lowest of the 6 companies compared; the peer median is 74.1%.
  • Its year-over-year change of +490439.7 pp is the highest of 5, against a peer median of +10.1 pp.
  • Over three fiscal years its change of +2555.9 pp compares with a peer median of -6.0 pp.
FDMT Competitors Peer median
Gross Margin for FDMT and competitors
Company Period LTM level YoY 3-year change
OCGNOcugen, Inc.LTM Mar 2026100.0% +0.0 pp-54.1 pp
MGTXMeiraGTx Holdings plcLTM Mar 202691.6% +64.6 pp-6.0 pp
QUREuniQure N.V.LTM Mar 202674.1% +20.2 pp-7.3 pp
ABEOAbeona Therapeutics Inc.LTM Mar 202651.9% —+5.5 pp
RGNXREGENXBIO Inc.LTM Mar 2026-0.1% -76.7 pp+36.5 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
SLDBSolid Biosciences Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding FDMT) 74.1%+10.1 pp-6.0 pp

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.04M3.13M20.72M37K85.21M
Cost of Revenue61.36M80.25M97.1M141.3M7.63M
Gross Profit(43.32M)(77.12M)(76.37M)(141.26M)77.58M
Gross Margin-240.2%-2464.8%-368.5%-381789.2%91.1%
Research & Development61.36M80.25M97.1M141.3M195.7M
Selling, General & Admin28.01M32.91M36.49M46.58M49.06M
Operating Expenses28.01M32.91M36.49M46.58M237.13M
Depreciation & Amortization1.52M2.4M4.2M6.71M7.63M
EBITDA(69.79M)(105.09M)(96.63M)(154.16M)(132.48M)
EBITDA Margin-386.9%-3358.6%-466.3%-416656.8%-155.5%
Operating Income(71.33M)(110.03M)(112.87M)(187.84M)(159.55M)
Operating Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%
Interest Income137K2.57M12.21M27.05M19.48M
Interest Expense00000
Other Income / Expenses16K2.54M12.03M26.97M19.44M
Income Before Tax(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Pre-Tax Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
Income Tax Expense00000
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Net Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
EPS (Basic)(2.46)(3.12)(2.58)(2.98)(2.42)
EPS (Diluted)(2.46)(3.12)(2.58)(2.98)(2.42)
Weighted Avg Shares27.73M32.35M39.13M53.94M57.93M
Weighted Avg Shares (Diluted)27.73M32.35M39.13M53.94M57.93M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.